aidsmap | A pair of antibodies keeps HIV undetectable by ‘bolting the door and masking the key’
A combination of two new antibodies that disrupt the interaction between the virus and the cells maintained viral suppression in most participants for up to six months, a study has found. Participants replaced their usual daily HIV medication with an infusion of the antibodies once every eight weeks.
Dr Martin Markowitz of Columbia University in New York presented the findings at HIV Glasgow 2026. The study, conducted with colleagues at six clinics across the United States, was simultaneously published in The Lancet HIV.
View all aidsmap reports from HIV Glasgow 2026
Life4me+ | New HIV antibody treatment shows promise — but who would benefit most?
An experimental HIV treatment administered intravenously every eight weeks maintained viral suppression in most participants in a small clinical study. At HIV Glasgow 2026, however, a key question emerged: Who would actually benefit from a treatment that still requires regular clinic visits?
Modern antiretroviral therapy has transformed HIV into a manageable chronic condition. Yet researchers continue to explore alternatives that could simplify long-term treatment, particularly for people managing multiple health conditions.
View all Life4me+ reports from HIV Glasgow 2026
Related HIV and Co-Infections News
-
[HIV Glasgow 2026] aidsmap | European guidelines widen access to two-drug HIV treatment
-
[HIV Glasgow 2026] aidsmap | Dolutegravir resistance has not risen in Lesotho cohort
-
[HIV Glasgow 2026] Infectious Disease Special Edition | Bixlenvo maintains viral suppression even among patients with preexisting resistance mutations
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.